
Nyxoah SA (NYXH) Stock Forecast & Price Target
Nyxoah SA (NYXH) Analyst Ratings
Bulls say
Nyxoah is well-positioned for future success as the company has demonstrated strong revenue growth and cost control, as evidenced by its above-street FY26 revenue guidance and good op ex control in Q1. The company also has positive momentum with its U.S. launch, showing strong indicators such as high-volume account adds, positive value analysis committee results, and no reimbursement rejections. With multiple upcoming catalysts, including the completion of its ACCCESS study and potential label expansion, Nyxoah has the potential to drive further investor confidence and solidify its position in the medtech category.
Bears say
Nyxoah is a health-technology company with a successful U.S. commercial launch, leading to an Overweight rating and $11 price target. Additionally, the pending ACCCESS study results in late June 2026/early July 2026 could open up new opportunities for expansion in 2027 for the company.
This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.
Nyxoah SA (NYXH) Analyst Forecast & Price Prediction
Start investing in Nyxoah SA (NYXH)
Order type
Buy in
Order amount
Est. shares
0 shares